SpringWorks Therapeutics (NASDAQ:SWTX) Shares Up 6.9%

SpringWorks Therapeutics (NASDAQ:SWTX) shot up 6.9% during mid-day trading on Monday . The company traded as high as $20.81 and last traded at $20.60, 110,200 shares traded hands during trading. A decline of 45% from the average session volume of 200,452 shares. The stock had previously closed at $19.27.

A number of research firms recently issued reports on SWTX. Wedbush assumed coverage on SpringWorks Therapeutics in a report on Tuesday, October 8th. They set an “outperform” rating and a $33.00 price target on the stock. Goldman Sachs Group assumed coverage on SpringWorks Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $37.00 price objective on the stock. Cowen assumed coverage on SpringWorks Therapeutics in a report on Tuesday, October 8th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on SpringWorks Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $32.00 price objective on the stock.

In other SpringWorks Therapeutics news, Director Stephen P. Squinto acquired 275,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $4,950,000.00. Also, major shareholder Bain Capital Life Sciences Inv acquired 150,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $2,700,000.00.

About SpringWorks Therapeutics (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Article: Understanding Options Trading

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.